Pharmaceutical Technology

JUNE 14, 2023

This, coupled with small pharma companies being unable to acquire or access containment capabilities in-house, means that the demand for innovative specialized small molecule capabilities remains high. Premium specialized equipment is necessary because high containment facilities call for the separation of the operator from the product.

Containment 130

Containment Manufacturing Contract Manufacturing Bioavailability 130

Pharmaceutical Technology

APRIL 12, 2023

Evidence suggests that API manufacturing is gaining in complexity, as well as sophistication, and therefore adding to the risk profile of drug development. The ingredients used in these drugs are high potency, even at small doses, and pose a risk to both human health and cross-contamination with other drugs in a manufacturing environment.

Manufacturing 130

Manufacturing Production Containment Contamination 130

Pharmaceutical Technology

MARCH 7, 2023

Safety issues must also be addressed, such as containment and potential ignition factors. Each of the aforementioned factors, alone, or with several combined, can offer manufacturers a unique challenge to obtaining a desired dosing rate or satisfactory product flow.

Production 130

Production Containment Bioavailability Manufacturing 130